The Mylan EpiPen Debacle: How Tremendous Greed Can Lead to the Demise of a Leader
N2Growth Blog
AUGUST 30, 2016
Through shrewd marketing efforts, failed competitors and helpful legislation (which requires its availability at public schools), Mylan has cornered the market on this allergy medication. And against that, manufacturing the product, distributing the product, enhancing the product, investing.” So $137 per pen.
Let's personalize your content